Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.
Drug-related pneumonitis in patients receiving Vedolizumab therapy for Inflammatory Bowel Disease / D. Pugliese, G. Privitera, T. Schepis, L. Larosa, S. Onali, F. Scaldaferri, A. Gasbarrini, F. Caprioli, A. Armuzzi. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - (2021). [Epub ahead of print] [10.1016/j.cgh.2021.08.041]
Drug-related pneumonitis in patients receiving Vedolizumab therapy for Inflammatory Bowel Disease
F. Caprioli;
2021
Abstract
Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1542356521009216-main.pdf
Open Access dal 01/09/2022
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
622.45 kB
Formato
Adobe PDF
|
622.45 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
